RTEPROST: Telephone Paramedical Support Prior to the Radiotherapy Simulation Scanner for Patients With Prostate Cancer
Study Details
Study Description
Brief Summary
The goal of this clinical trial is to evaluate the impact of a phone call before the simulation CT scan in management of care of patients with prostate cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
After being informed about the study, all patients who have given written informed consent and who met eligibility requirement will be randomized in a simple blind manner ( investigator) in a 1:1 ration.
The main question it aims to answer is : Does a phone call before the simulation CT scan has an effectiveness on patients compliance of the recommendations and therefore on obtaining quality images.
There is no additional risk of patients involvement.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Patient with standard care Consultation with the onco radiotherapeutic and submission of the recommendations to follow before the simulation CT Scan before the radiotherapy |
|
| Experimental: Patient with personalized support Consultation with the onco radiotherapeutic and submission of the recommendations to follow before the simulation CT Scan before the radiotherapy and a phone call by a radiotherapy technician |
Other: Phone call
In the experimental arm the patient will be called 3 days before the CT scan
|
Outcome Measures
Primary Outcome Measures
- Assess the value of a telephone call in terms of compliance recommendations for preparation (empty rectum and full bladder) necessary to perform the CT scanner simulation in the management of patients with prostate cancer. [From the day of the consultation with the radiotherapist to the day of the CT scanner, up to three month after the inclusion]
The proportion of patients for whom it is necessary to renew the CT scanner simulation.
Secondary Outcome Measures
- Assess the impact of a telephone call upstream of the simulation scanner on patient preparation according to recommendations. [From the day of the consultation with the radiotherapist to the day of the CT scanner, up to three month after the inclusion]
The number of patients who performed the preparation for the scanner.
- Assess the impact of a telephone call upstream of the simulation scanner on reading the recommendation sheet given to the patient during the announcement medical consultation. [From the day of the consultation with the radiotherapist to the day of the CT scanner, up to three month after the inclusion]
The number of patients who read the recommendations
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult
-
Patient coming for prostate cancer treatment with or without lymph node irradiation
-
Minimum of 48 hours between the onco radiotherapist and the CT scan
-
Signed a written informed consent form
-
Affiliated to the social security system
Exclusion Criteria:
-
Patient not understanding French
-
Patient not reachable by phone
-
Individual of full age deprived of liberty or placed under a legal protection measure
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hôpital du Scorff | Lorient | Bretagne | France | 56100 |
Sponsors and Collaborators
- Groupe Hospitalier de Bretagne Sud
Investigators
- Principal Investigator: Rosalie GUEGAN, GHBretagne sud
Study Documents (Full-Text)
None provided.More Information
Publications
- de Crevoisier R, Tucker SL, Dong L, Mohan R, Cheung R, Cox JD, Kuban DA. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):965-73. doi: 10.1016/j.ijrobp.2004.11.032.
- Maggio A, Gabriele D, Garibaldi E, Bresciani S, Delmastro E, Di Dia A, Miranti A, Poli M, Varetto T, Stasi M, Gabriele P. Impact of a rectal and bladder preparation protocol on prostate cancer outcome in patients treated with external beam radiotherapy. Strahlenther Onkol. 2017 Sep;193(9):722-732. doi: 10.1007/s00066-017-1163-4. Epub 2017 Jun 15.
- 56LORC_2021_RTEPROST